We are live on ! Find out more
TSVT icon

2seventy bio

Delisted

TSVT was delisted on the 13th of May, 2025.

133 hedge funds and large institutions have $494M invested in 2seventy bio in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 37 increasing their positions, 36 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

309% more call options, than puts

Call options by funds: $2.26M | Put options by funds: $552K

3% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 36

1% more funds holding

Funds holding: 132 → 133 (+1)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2.45% less ownership

Funds ownership: 92.03% → 89.58% (-2.5%)

16% less capital inflows, than outflows

Capital inflows: $52.7M | Capital outflows: $62.8M

18% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 17

Holders
133
Holders Change
+1
Holders Change %
+0.76%
% of All Funds
2.28%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
37
Reduced
36
Closed
17
Calls
$2.26​M
Puts
$552​K
Net Calls
+$1.71​M
Net Calls Change
+$1.89​M

TSVT Hedge Fund Activity: Q3 2022 in Review

133 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q3 2022, worth a combined $494M — up 8% from $457M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of TSVT and 14 opened new positions — a net loss of 3 holders — while 36 trimmed existing stakes and 37 added.

The largest buyer was OrbiMed, opening a new position worth an estimated $15.5M. The largest seller was EcoR1 Capital, cutting an estimated $17.1M.

  • 133 institutional investors held 2seventy bio (TSVT) as of Q3 2022, up from 132 in Q2 2022.
  • Funds reported $494M of 2seventy bio stock for Q3 2022, up 8% quarter-over-quarter.
  • 14 funds opened new 2seventy bio positions in Q3 2022 and 17 closed out, a net change of -3 holders.
  • The largest 2seventy bio buyer in Q3 2022 was OrbiMed, an estimated $15.5M added.
  • The largest 2seventy bio seller in Q3 2022 was EcoR1 Capital, an estimated $17.1M sold.

Based on aggregated 13F filings for Q3 2022.